Cancer Screening
LucenceINSIGHT®
LucenceINSIGHT® is a multi-cancer early detection (MCED)
next-generation sequencing (NGS) blood test that screens for up to 50 cancers with 99% specificity (low false-positives). This test can screen for multiple high-incidence and high-risk cancers simultaneously from a single blood draw, including lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, nasopharyngeal cancer, bile duct cancer, and pancreatic cancer.
The test uses Lucence's mirror barcoding technology to detect ctDNA, ctRNA, and viral DNA. It can then predict tumor location with machine learning.
LucenceINSIGHT® Core
$5,000
Essential Screening
Focused on what matters most.
(Detect 6 high impact cancers)
LucenceINSIGHT® Me
$7,200
Personalized Cancer Screening
Personalized screening for signals associated with 9 cancer types, accounting for up to 75% of global cancer mortality. It combines LucenceINSIGHT Core with 3 additional selections from a curated list of 12 cancers. *Cancers in dark blue are the 12 available options from which 3 can be selected for LucenceINSIGHT Me.
LucenceINSIGHT® Me
LucenceINSIGHT® 12
$13,000
Smarter Ccreening.
Tailored for each gender.
Detect 12 cancers (including gender-specific)
LucenceINSIGHT® 50
$22,000
Comprehensive Screening
Designed for peace of mind
Detect 50 cancers accounting for >90% of global cancer mortality.(1)
NOTE:
-
Lucence INSIGHT® is designed to screen for signals associated with cancer; it is not a diagnostic test. A positive result should always be followed by appropriate confirmatory diagnostic testing
-
Lucence INSIGHT® does not assess inherited or familial cancer risk, such as genetically predisposed breast cancer.
-
This test is not a substitute for standard cancer screening. It is intended to complement, not replace, routine screening tests recommended by a healthcare professional.
-
False-positive and false-negative results may occur. False-negative results can arise from biological factors, including low levels of DNA shedding or small tumour size. If follow-up testing does not confirm cancer, it may indicate that cancer is not present or that the confirmatory testing was insufficient to detect the cancer signal.
-
Lucence INSIGHT® screens only for the specific cancers indicated. It does not rule out the possibility of other cancers not detected by the test.
-
Lucence INSIGHT® is not recommended for individuals who are pregnant or who have had a history of cancer within the past three years.